PTBET was featured at the TEDD Annual Meeting 2025
© 2025 EPFL
Dr. Gaspard Pardon, head of the EPFL Bioengineering & Organoids Technology platform (PTBET) at the AGORA Cancer Research Center in Lausanne, was invited to speak at the TEDD Annual Meeting 2025 entitled "Advancing Biomedical Research with NAMs (New Approach Methodologies): Innovations and Applications in Switzerland," held on August 27 at the ZHAW campus in Wädenswil (Zurich).
TEDD is a national competence center for education, R&D, and networking that promotes the application of advanced 3D organotypic technologies in therapy development. Its core mission is to replace animal experimentation in line with the 3Rs principles (Replacement, Reduction, Refinement) by fostering collaboration and advancing translational R&D across academia, clinics, and industry.
In his talk, “Advancing Translational Research with Bioengineering and Organoids Technology,” Dr. Pardon presented the activities and collaborations of the PTBET platform, highlighting work on organoids, organ-on-chip systems, and assay development. His presentation emphasised PTBET’s strategic role at AGORA as a provider of technical expertise and shared facilities that drive collaboration and innovation at the interface of bioengineering and cancer research.